Europe's medicines advisers have backed a six-weekly dosing schedule for Regeneron's cemiplimab, a change that would apply across all of the drug's EU indications. The CHMP, the European Medicines Agency's Committee for Medicinal Products for Human Use, issued a positive opinion supporting the less-frequent schedule for the anti-PD-1 therapy marketed by Regeneron.

The decision matters for a simple reason. Patients on cemiplimab today travel to infusion centers on a tighter cycle. A six-weekly interval would cut the number of clinic visits roughly in half over a year, easing the treatment burden for people on long-term immunotherapy.

What does the CHMP opinion cover?

The positive opinion applies across cemiplimab's approved EU indications, meaning the flexibility would not be limited to a single tumor type or patient subgroup. That breadth is the story here: rather than a narrow label tweak, the committee has endorsed the extended interval wherever the drug is already used.

A CHMP positive opinion is the final advisory step before formal approval. If the European Commission follows the recommendation, as it routinely does, the six-weekly schedule would become available to prescribers across EU member states.

Why does dosing interval matter in practice?

For dermatology and oncology clinics, the change is operational as much as clinical. Fewer infusion visits mean:

• Fewer chair-hours per patient per year in busy infusion units
• Reduced travel and time costs for patients on maintenance therapy
• Scheduling flexibility for combination sequences and follow-up visits

Immunotherapy patients often remain on treatment for months or years. Over that horizon, the difference between more frequent and six-weekly visits compounds — for patients, it can mean dozens of extra clinic trips avoided; for centers, meaningful capacity recovered.

Who is behind the drug?

Regeneron developed cemiplimab, its anti-PD-1 checkpoint inhibitor. The company has pursued the extended dosing interval as part of a broader effort to make long-term immunotherapy more workable for patients and health systems.

Regeneron has not yet commented publicly on a launch timeline for the new schedule in individual EU markets, and the exact effective date will depend on the European Commission's formal decision.

What happens next?

The European Commission will now consider the CHMP's opinion. Approval would put cemiplimab on an every-six-weeks footing across the EU, aligning European practice with the global trend toward extended-interval checkpoint inhibitor dosing — a shift that trial data and regulators are increasingly willing to support.